Focus Partners Advisor Solutions LLC Acquires New Holdings in Medpace Holdings, Inc. $MEDP

Focus Partners Advisor Solutions LLC bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 2nd quarter, Holdings Channel.com reports. The fund bought 3,182 shares of the company’s stock, valued at approximately $1,685,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MEDP. BOKF NA lifted its holdings in shares of Medpace by 0.8% in the third quarter. BOKF NA now owns 2,542 shares of the company’s stock valued at $1,307,000 after purchasing an additional 20 shares in the last quarter. Valeo Financial Advisors LLC raised its position in shares of Medpace by 5.0% during the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock worth $249,000 after purchasing an additional 21 shares during the last quarter. UMB Bank n.a. lifted its stake in Medpace by 5.6% in the 4th quarter. UMB Bank n.a. now owns 450 shares of the company’s stock valued at $253,000 after buying an additional 24 shares in the last quarter. Schulhoff & Co. Inc. lifted its stake in Medpace by 1.1% in the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock valued at $1,237,000 after buying an additional 25 shares in the last quarter. Finally, Balefire LLC grew its holdings in Medpace by 6.1% during the 1st quarter. Balefire LLC now owns 451 shares of the company’s stock valued at $217,000 after buying an additional 26 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Insider Activity at Medpace

In related news, Director Cornelius P. Mccarthy III sold 1,140 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $605.37, for a total value of $690,121.80. Following the completion of the sale, the director directly owned 12,275 shares in the company, valued at approximately $7,430,916.75. The trade was a 8.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO August J. Troendle sold 17,610 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $605.11, for a total transaction of $10,655,987.10. Following the transaction, the chief executive officer directly owned 615,802 shares of the company’s stock, valued at $372,627,948.22. This trade represents a 2.78% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 67,195 shares of company stock worth $37,989,998. 20.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on MEDP shares. Royal Bank Of Canada raised their price target on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Robert W. Baird upped their price objective on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. Barclays set a $600.00 price objective on Medpace in a research note on Thursday, July 23rd. BMO Capital Markets lifted their price objective on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research report on Friday, July 24th. Finally, Leerink Partners set a $620.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Three analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $584.18.

Medpace Stock Down 0.6%

Shares of Medpace stock opened at $578.50 on Friday. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The business’s fifty day moving average is $536.23 and its two-hundred day moving average is $492.35. The firm has a market cap of $16.15 billion, a PE ratio of 33.91, a P/E/G ratio of 2.58 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. During the same quarter in the previous year, the business earned $3.10 earnings per share. The business’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities research analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.